We are excited to congratulate the Hong Kong Med-Tech Association (HKMTA) on their new name, reflecting a stronger focus on technology. Our President and Managing Director, Jennifer Che, along with Principal Pauli Wong, were thrilled to celebrate this significant milestone with the organization at the recent HKMHDIA Medical Fair Forum.

Pauli, the official IP Advisor to HKMTA, joined Jennifer, one of the keynote speakers at the event, who shared about the importance of a well-thought-out intellectual property strategy for healthcare inventions. Jennifer emphasized the challenges of protecting biomedical products that operate at the intersection of regulatory affairs, IP, trade secret, and data privacy, particularly in the complex, multijurisdictional landscape of the Greater Bay Area (GBA). The event fostered valuable discussions on navigating these complexities, reinforcing our commitment to helping innovators safeguard their groundbreaking ideas.

我們過去活動

Recommended Insights

Diagnostic Claims in China

2020年1月9日
The Chinese Patent Law excludes patenting methods of diagnosing or treating a disease. More specifically, this refers to processes of identifying, determining, or eliminating the cause or focus of diseases which are practiced directly on living human or animal bodies. Please keep in mind that instruments used for implementing these methods are still patentable. So […]

China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux

2021年5月24日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

2021年6月9日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

Stay Ahead: Getting a Chinese Patent in Three Months?

2024年4月23日
The China National Intellectual Property Administration (CNIPA) has announced a significant development in the realm of patent prosecution: the initiation of the "PPH Improvement Initiative" in collaboration with key patent offices from the United States, Europe, Japan, and South Korea. This initiative aims to elevate the user experience of the Patent Prosecution Highway (PPH) by […]
Top crossarrow-right